Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

Fig. 2

Binding affinity of GIP, GLP-1, and the dual (GIP and GLP-1 receptor) co-agonist tirzepatide (formerly named LY3298176) to human embryonic kidney (HEK 293) cells transfected with human GIP and GLP-1 receptors, and potency in stimulating cyclic adenosine mono-phosphate (cAMP) accumulation. Data have been taken from Coskun et al. 2018 [13] and are expressed as EC50 (effective concentration resulting in half-maximal stimulation) or Ki (inhibitory constant, leading to half-maximal displacement of tracer)

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840